R-PR File For Campto Approvals In 13 EU Countries

4 August 1996

- Rhone-Poulenc Rorer has submitted marketing applications in 13 European Union countries for Campto (irinotecan/CPT-11), its treatment for advanced metastatic colorectal cancer which has failed to respond to standard chemotherapy with 5-flourouracil and folinic acid. The cancer was stabilized in 42% of the 455 patients after a median duration of five months. Side effects include moderate-to-severe diarrhea and neutropenia. The drug was recently approved in the USA where it is licensed to Pharmacia & Upjohn.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight